Weight-loss jabs sharpen a class divide among middle-aged women
TL;DR Summary
New Health Foundation data shows middle-class women aged 30–50 are the dominant private-prescription users of weight‑loss injections like Ozempic and Mounjaro, prompting debate over affordability, ethics, and long-term health effects as researchers highlight side effects and a growing class divide in obesity treatment.
- The big fat jab divide: why middle-class women are buying them The Times
- Middle-class women aged 30-50 are main buyers of weight-loss drugs The Times
- Women and middle classes dominate weight loss jab take-up Sky News
- The people most likely to use weight loss jabs, according to new research The Independent
- GLP-1 rollout could widen health inequalities, warns Health Foundation Healthcare Leader
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
30 min
vs 31 min read
Condensed
99%
6,128 → 43 words
Want the full story? Read the original article
Read on The Times